论文部分内容阅读
目的探讨流式细胞术检测多发性骨髓瘤中骨髓细胞表面免疫表型的价值。方法选取2016年1月至2017年1月间四川省川北医学院附属医院收治的67例多发性骨髓瘤患者为研究对象,对照组为同期就诊的51例继发性单克隆免疫球蛋白血症患者。检测并比较两组患者骨髓细胞表面CD19、CD38、CD45、CD56和CD138的表达情况,比较骨髓瘤细胞和正常细胞的鉴别价值。结果骨髓瘤组患者CD38和CD138的荧光强度分别为(782.4±154.2)%和(981.9±228.1)%,高于对照组患者的(555.4±101.8)%和(613.2±128.9)%,骨髓瘤组患者CD19的荧光强度为(59.1±24.3)%,低于对照组患者的(357.0±128.4)%,差异均有统计学意义(均P<0.05)。CD19阳性率为0.0%(0/67),CD38阳性率为100.0%(67/67),为强表达;CD45阳性率为3.0%(2/67),为弱表达;CD56阳性率为30.9%(21/67),为高表达;CD138阳性率为100.0%(67/67),为强表达。结论通过流式细胞术检测骨髓瘤细胞免疫表型,可以鉴别骨髓瘤细胞和正常细胞,在多发性骨髓瘤的诊断中具有重要作用。
Objective To investigate the value of flow cytometry in detecting the immunophenotype of bone marrow cells in multiple myeloma. Methods Sixty-seven patients with multiple myeloma who were treated at Affiliated Hospital of Sichuan North Sichuan Medical College between January 2016 and January 2017 were selected as the study subjects. The control group consisted of 51 patients with secondary monoclonal immunoglobulinuria patient. The expression of CD19, CD38, CD45, CD56 and CD138 on the surface of bone marrow cells in both groups were detected and compared, and the differential value of myeloma cells and normal cells was compared. Results The fluorescence intensity of CD38 and CD138 in myeloma group were (782.4 ± 154.2)% and (981.9 ± 228.1)%, respectively, higher than that in control group (555.4 ± 101.8) and (613.2 ± 128.9)% The fluorescence intensity of CD19 was (59.1 ± 24.3)%, which was lower than that of the control group (357.0 ± 128.4)%, the differences were statistically significant (all P <0.05). The positive rate of CD19 was 0.0% (0/67), the positive rate of CD38 was 100.0% (67/67), which was strongly expressed. The positive rate of CD45 was 3.0% (2/67), which was weakly expressed. The positive rate of CD56 was 30.9% (21/67), high expression; CD138 positive rate was 100.0% (67/67), strong expression. Conclusion The detection of myeloma cell immunophenotype by flow cytometry can differentiate myeloma cells from normal cells and play an important role in the diagnosis of multiple myeloma.